Intanza®, the First Intradermal Influenza Vaccine, receives the European Marketing Authorisation

Intanza®, the First Intradermal Influenza Vaccine, receives the European Marketing Authorisation

Intanza®, the first seasonal flu vaccine delivered by intradermal microinjection, has been granted a marketing authorisation by the European Commission.

Intanza® is approved for use in adults 60 years of age and older, especially in those who run an increased risk of influenza-associated complications. With ageing, the immune system tends to weaken - older adults become not only more susceptible to infections but also less responsive to vaccination, a phenomenon known as immunosenescence.

The intradermal administration of Intanza® provides a direct and effective access to the immune system through the dermal skin layer, where there is a high concentration of specialised immune cells and extensive vascularized network, leading to a synergistic activation of immune responses. The pre-filled and ready-to-use microinjection system* with a very short needle enables accurate and reliable delivery into the dermis. "We are pleased to offer the elderly and their doctors this new vaccine which should contribute to improve the prevention from an underestimated disease that continues to kill people and to cause serious complications", says Yves Mégard, Director Medical Affairs for adult and senior vaccines at Sanofi Pasteur MSD.

The application for marketing authorisation for Intanza® was supported by the results of clinical trials involving more than 7,000 adults and elderly participants. These trials evaluated the safety and ability to generate an immune response of this novel seasonal influenza vaccine. Intanza® generated a high level of immunity against all tested influenza strains in participants older than 60 years.

Sanofi Pasteur MSD will market Intanza® within Western Europe†. Outside this territory, the vaccine will be marketed by Sanofi Pasteur, one of Sanofi Pasteur MSD's parent companies.